ONCODAILY MEDICAL JOURNAL

abstract

Improving the Outcome of Pediatric ALL by Transitioning From Nonuniform Chemotherapy Regimens to a Uniform Multicentric Protocol: A Comprehensive Experience from an Indian Center on the ICiCLe Protocol

Debabrata Mohapatra, Rachna Seth, Amitabh Singh, Prashant Prabhakar, Nivedita Pathak, Manisha Aggarwal, et. al.

DOI: 10.69690/ODMJ-018-0425-1174



ONCODAILY MEDICAL JOURNAL

abstract



Impact of Monocular Enucleation on Functional Vision in Retinoblastoma Patients

Author: Debabrata Mohapatra, Rachna Seth, Amitabh Singh, Prashant Prabhakar, Nivedita Pathak, Manisha Aggarwal, et. al.

Affiliation: All India Institute of Medical Sciences, New Delhi

DOI: 10.69690/ODMJ-018-0425-1174

Introduction: Although the five-year survival of pediatric acute lymphoblastic leukemia (ALL) exceeds 90% in high-income countries, outcomes in lower- and middle-income countries (LMICs), remain inconsistent due to including India, abandonment, challenges, like: treatment undernutrition, and therapy-related toxicity. To address these disparities, the Indian Collaborative Childhood Leukemia (ICiCLe) group developed a multicentric, risk-adapted protocol tailored for Indian settings.

Methodology: This retrospective, observational study from a single center evaluated outcomes of pediatric ALL patients treated before and after adopting the ICiCLe protocol. Patients were divided into two groups: those treated with various nonuniform protocols (Group 1: 2013–2014, before initiation of ICiCLe protocol) and those treated under the ICiCLe protocol (Group 2: 2015–2022). Additional adaptations made during the implementation of ICiCLe protocol included: outpatient management of febrile neutropenia, active patient-tracking during treatment, telecon-

sultation and socio-economic support. Outcome parameters included disease-free survival (DFS), overall survival (OS), minimal residual disease (MRD) and predictors of survival.

Results: Group 2 (n=356) had more high-risk patients than Group 1 (n=115) i.e. 44.1% vs 35.65%; which is also reflected in the minimal residual disease (MRD) positivity (9.1% vs 21.1%). Except for the T-ALL subset, the rest of the baseline characteristics were comparable for both groups. The three-year DFS and OS increased from 62.27(51.39-71.39) % and 62.84(53.04-71.16) % in Group 72.53(66.30-77.81) 1 to and 74.51(68.56-79.50) % in Group 2, respectively. Predictors of improved survival included MRD response [HR=2.163(1.372-3.409), p=0.001] and adherence uniform to use of protocol [HR=0.642(0.427-0.964), p=0.033].

Conclusion: This study highlights the transformative potential of standardized, resource-adapted protocols in LMICs, demonstrating improved survival rates for pediatric ALL. While showcasing the

benefits of standardized care, it highlights the need for ongoing adaptations and multicentric collaborations to meet the global standards in terms of survival in childhood ALL in resource-constrained settings.